Amgen 2Q Revenues: $6.5 billion (+5%) 2Q Earnings: $464 million (-74%) Comments: Product sales increased 3% globally, driven by double digit volume growth across a several products including Prolia (denosumab) up 24% to $814 million, Repatha up 43% to $286 million, and biosimilar products MVASI up 71% to $294 million, and KANJINTI up 27% to $156 million. EVENITY sales increased 30% to $131 million. Aimovig sales were down 16% to $82 million. Otezla sales were $534 million, down 5%. Enbrel sal...